[Recombinant activated C protein for severe sepsis]

Wild, C. (2005): [Recombinant activated C protein for severe sepsis]. HTA-Newsletter 38: p. 4.

Preview

PDF (HTA-Newsletter 38) - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
110kB

Item Type:	HTA Newsletter Item
Keywords:	Drotrecogin alfa (Xigris®), activated C protein, drug therapy, severe sepsis, blood poisoning, safety, costs
Subjects:	WC Communicable diseases
Related URLs:	http://www.oeaw.ac.at/ita/hta-news.htm
References:	1. NCCHTA/GB 2005: Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris (R)) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. URL: http://www.ncchta.org/execsumm/summ911.htm. 2. NICE/GB 2004: Drotrecogin alfa (activated) for severe sepsis. URL: http://www.nice.org.uk/pdf/TA084guidance.pdf. 3. CAHTA/SP 2004: Assessment of the scientific evidence on the use of recombinant activated C protein – (activated) alphadrotrecogin – in severe sepsis. URL: http://www.gencat.net/salut/depsan/units/ aatrm/pdf/ct0401en.pdf. 4. SBU/SE 2003: Drotrecogin alfa (Xigris®) for severe sepsis. URL: http://www.sbu.se/www/index.asp?ReportID=779&from=Subpage.asp?CatID%3D60%26PageID%3D319&typeID=3.
Language:	German
Number:	38
Deposited on:	21 Jan 2008 15:41
Last Modified:	15 Jul 2020 17:35

Repository Staff Only: item control page